抑制PARP1活性对博来霉素诱导的肺纤维化的改善作用

doi:10.13481/j.1671-587x.20150302

吉林大学学报(医学版) ›› 2015, Vol. 41 ›› Issue (03): 442-447.doi: 10.13481/j.1671-587x.20150302

抑制PARP1活性对博来霉素诱导的肺纤维化的改善作用

赵岩¹, 林添雨², 孙茹³, 韩延龙², 米东辉⁴, 曾宪录², 巴雪青²

1. 吉林省疾病预防控制中心媒介生物防治科, 吉林长春 130061;
2. 东北师范大学遗传与细胞研究所, 吉林长春 130024;
3. 吉林大学体育学院, 吉林长春 130012;
4. 吉林大学中日联谊医院呼吸科, 吉林长春 130033

收稿日期:2015-01-02 发布日期:2015-08-01
通讯作者: 巴雪青,教授,博士研究生导师(Tel:0431-85098837,E-mail:baxq755@nenu.edu.cn) E-mail:baxq755@nenu.edu.cn
作者简介:赵岩(1966-),男,吉林省长春市人,副主任技师,主要从事炎症相关的信号转导及基因表达调控方面的研究。
基金资助:
国家自然科学基金面上项目资助课题(31371293);吉林省科技厅科技发展计划国际科技合作项目资助课题(20120728)

Ameliorative effect of PARP1 inhibition on bleomycin- induced pulmonary fibrosis

ZHAO Yan¹, LIN Tianyu², SUN Ru³, HAN Yanlong², MI Donghui⁴, ZENG Xianlu², BA Xueqing²

1. Department of Vector Prevention and Control, Center of Disease Prevention and Control, Jilin Province, Changchun 130061, China;
2. Institute of Genetics and Cytology, Northeast Normal University, Changchun 130024, China;
3. School of Physical Education, Jilin University, Changchun 130012, China;
4. Department of Respiratory Medicine, China-Japan Union Hospital, Jilin University, Changchun 130033, China

Received:2015-01-02 Published:2015-08-01

摘要/Abstract

摘要：

目的:探讨抑制聚ADP核糖多聚酶1(PARP1)活性对于博莱霉素导致的肺纤维化的改善作用,阐明抑制PARP1活化改善肺纤维化的作用机制。方法:48只雌性ICR小鼠随机分为对照组(腹腔注射生理盐水)和5、10、15 mg·kg^-1博莱霉素组(模型组)。3个模型组分别在第1、4、8、11、15、18、22和25天腹腔注射相应浓度的博莱霉素。60只雌性ICR小鼠随机分成对照组、10 mg·kg^-1博莱霉素模型组及不同剂量PARP1抑制剂PJ34治疗组(腹腔注射博来霉素20min前尾静脉注射1、5和10 mg·kg^-1 PJ34)。上述实验中,分别于第14、21和28天每组选取3只小鼠,处死后取肺。HE染色观察肺泡结构,Masson染色分析纤维化程度。肺上皮源性细胞A549用于博莱霉素刺激后,Real-time PCR法分析PJ34对上皮间充质转化(EMT)标志基因表达的影响。结果:与博莱霉素模型组比较,PJ34治疗组小鼠肺泡结构的破坏及胶原在肺间质中的沉积明显减轻;Real-time PCR法分析,与博莱霉素模型组比较,PJ34治疗组肺上皮细胞A549中E-cadherinmRNA表达水平升高(P<0.05),α-SMA和TGF-βmRNA表达水平下降(P<0.05或P<0.01)。结论:抑制PARP1活性可以影响EMT标志基因的表达及肺纤维化的产生,PARP1抑制剂可用于预防博来霉素治疗肿瘤过程中产生的肺纤维化。

关键词: 博莱霉素, 肺纤维化, 聚ADP核糖聚合酶1, 上皮间质转化

Abstract:

Objective To determine the intervention effect of poly(ADP-ribose) polymerase 1 (PARP1) inhibition on the bleomycin(BML)-induced pulmonary fibrosis in anti-tumor therapies, and to further elucidate the mechanisms of anti-fibrosis role of PARP1 inhibition. Methods Forty eight female ICR mice were randomly divided into normal control (peritoneal injection of saline) and BLM groups (model groups) with doses of 5, 10 and 15 mg·kg^-1, respectively. BLM was peritoneally injected at day 1, 4, 8, 15, 18, 22 and 25. Sixty female ICR mice were randomly divided into normal control, 10 mg·kg^-1 BLM model group, and differeat doses(1, 5 and 10 mg·kg^-1) of PJ34-treated groups. BLM was administrated 20 min after intravenous injection of PARP1 inhibitor PJ34. In all above experiments, 3 mice were sacrificed at day 14, 21 and 28, the lungs were removed for histochemical analysis. HE staining was performed to detect the alveolar damage and Masson staining was performed to detects the collagen deposition. Moreover, A549 cells were exposed to BLM, and the effects of PARP1 inhibition on the expression of EMT biomarkers were detected by Real-time PCR. Results Compared with BLM model group, the alveolar damage and collagen deposition in the lung tissue of the mice in PJ34-treated group were effectively decreased. Compared with BLM group, the E-cadherin mRNA expression levels in A549 cells of the mice in PJ34-treated group was increased (P<0.05), and the expression levels of α-SMA and TGF-β mRNA were decreased(P<0.05 or P<0.01). Conclusion PARP inhibition can affect the expressions of EMT marker genes, and alleviate the BLM-induced pulmonary fibrosis, suggesting PARP1 inhibitors can be utilized to prevent the pulmonary fibrosis in the process of cancer therapy.

Key words: bleomycin, pulmonary fibrosis, poly(ADP-ribose) polymerase 1, epithelial-mesenchymal transition

中图分类号:

R563.9

赵岩, 林添雨, 孙茹, 韩延龙, 米东辉, 曾宪录, 巴雪青. 抑制PARP1活性对博来霉素诱导的肺纤维化的改善作用[J]. 吉林大学学报(医学版), 2015, 41(03): 442-447.

ZHAO Yan, LIN Tianyu, SUN Ru, HAN Yanlong, MI Donghui, ZENG Xianlu, BA Xueqing. Ameliorative effect of PARP1 inhibition on bleomycin- induced pulmonary fibrosis[J]. Journal of Jilin University Medicine Edition, 2015, 41(03): 442-447.

参考文献

[1] Chaudhary NI, Schnapp A, Park JE. Pharmacologic differentiation of inflammation and fibrosis in the rat bleomycin model [J]. Am J Respir Crit Care Med, 2006, 173(7):769-776.

[2] Wynn TA. Integrating mechanisms of pulmonary fibrosis [J]. J Exp Med, 2011, 208(7):1339-1350.

[3] Iyama T, Wilson DM 3rd. DNA repair mechanisms in dividing and non-dividing cells [J]. DNA Repair (Amst), 2013, 12(8):620-636.

[4] Ba X, Garg NJ. Signaling mechanism of poly(ADP-ribose) polymerase-1 (PARP-1) in inflammatory diseases [J]. Am J Pathol, 2011, 178(3):946-955.

[5] Liu L, Ke Y, Jiang X, et al. Lipopolysaccharide activates ERK-PARP-1-RelA pathway and promotes nuclear factor-kappaB transcription in murine macrophages [J]. Hum Immunol, 2012, 73(5):439-447.

[6] Li HY, Pan L, Ke YS, et al. Daidzein suppresses pro-inflammatory chemokine Cxcl2 transcription in TNF-alpha-stimulated murine lung epithelial cells via depressing PARP-1 activity [J]. Acta Pharmacol Sin, 2014, 35(4):496-503.

[7] Ba X, Gupta S, Davidson M, et al. Trypanosoma cruzi induces the reactive oxygen species-PARP-1-RelA pathway for up-regulation of cytokine expression in cardiomyocytes [J]. J Biol Chem, 2010, 285(15):11596-11606.

[8] Kage H, Borok Z. EMT and interstitial lung disease:a mysterious relationship [J]. Curr Opin Pulm Med, 2012, 18(5):517-523.

[9] Williamson JD, Sadofsky LR, Hart SP. The pathogenesis of bleomycin-induced lung injury in animals and its applicability to human idiopathic pulmonary fibrosis [J]. Exp Lung Res, 2015, 41(2):57-73.

[10] 辛维娜, 蒋荣娜, 石卓, 等.甘草酸二铵对博莱霉素致肺纤维化大鼠血清iNOS及NO水平的影响及其抗肺纤维化的作用机制[J].吉林大学学报:医学版, 2013, 39(1):38-41.

[11] Zhao H, Qin HY, Cao LF, et al. Phenylbutyric acid inhibits epithelial-mesenchymal transition during bleomycin-induced lung fibrosis[J]. Toxicol Lett, 2014, 232(1):213-220.

[12] Moore BB, Hogaboam CM. Murine models of pulmonary fibrosis [J]. Am J Physiol Lung Cell Mol Physiol, 2008, 294(2):L152-160.

[13] Virag L. Poly(ADP-ribosyl)ation in asthma and other lung diseases [J]. Pharmacol Res, 2005, 52(1):83-92.

[14] Di Paola R, Talero E, Galuppo M, et al. Adrenomedullin in inflammatory process associated with experimental pulmonary fibrosis [J]. Respir Res, 2011, 12(1):41-52.

[15] Wang Z, Wang F, Tang T, et al. The role of PARP1 in the DNA damage response and its application in tumor therapy [J]. Front Med, 2012, 6(2):156-164.

[16] Sonnenblick A, de Azambuja E, Azim HA Jr, et al. An update on PARPinhibitors-moving to the adjuvant setting [J]. Nat Rev Clin Oncol, 2015, 12(1):27-41.

[17] 魏路清, 彭守春.间质性肺疾病的生物学标志物研究进展[J]. 中国实用内科杂志, 2014, 34(8):748-751.

[18] 胡红, 刘又宁.糖皮质激素在呼吸疾病治疗中的应用[J].中国实用内科杂志, 2013, 33(10):764-767.

抑制PARP1活性对博来霉素诱导的肺纤维化的改善作用

Ameliorative effect of PARP1 inhibition on bleomycin- induced pulmonary fibrosis

RichHTML

PDF (PC)

赞

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 14

Metrics

本文评价

推荐阅读 0

[1]	石旭, 余欣, 曲兴龙, 曹扬, 张广娟, 李长远. 低氧及其下游因子miRNA-145在脐带间充质干细胞向Ⅱ型肺泡上皮细胞分化中的作用[J]. 吉林大学学报(医学版), 2018, 44(05): 935-942.
[2]	马啸天, 岳小欣, 荣守华, 张玉超, 田远, 石瑛, 李君芳, 贾莉婷. miR-200c对三阴性乳腺癌上皮间质转化的抑制作用及其机制[J]. 吉林大学学报(医学版), 2018, 44(01): 106-110.
[3]	谭婧瑾, 王瑞民, 姜杉, 姚月, 陈洋, 王珂. FGFR信号传导通路在特发性肺纤维化和非小细胞肺癌发病中作用机制的研究进展[J]. 吉林大学学报(医学版), 2016, 42(06): 1254-1258.
[4]	王艳, 王瑞民, 张庆华, 王珂. 间质性肺疾病与肺癌发病关联性的研究进展[J]. 吉林大学学报(医学版), 2016, 42(04): 830-834.
[5]	符良斌, 廖天安, 王鸿, 邓伟, 周斌, 王友元. TGF-β1对人舌鳞状细胞癌上皮-间质转化的诱导作用及其对PI3K/AKT信号通路的影响[J]. 吉林大学学报(医学版), 2015, 41(04): 790-793.
[6]	王司仪,原铭贞,刘笑玎,刘相良,高歌,梁豪君,李波,董春玲. 细胞因子与肺纤维化相关性的研究进展[J]. 吉林大学学报(医学版), 2014, 40(06): 1325-1329.
[7]	辛维娜，蒋荣娜，石卓，盛辉. 甘草酸二铵对博莱霉素致肺纤维化大鼠血清iNOS及NO水平的影响及其抗肺纤维化的作用机制[J]. 吉林大学学报(医学版), 2013, 39(1): 38-41.
[8]	杨俊玲\|赵凤莲\|薛倩菲\|蔡露. 糖尿病肺纤维化的研究进展[J]. J4, 2011, 37(2): 389-392.
[9]	吴春风，马忠森，王秀丽，杨广民，马寅芙，杨俊玲，尹金植，陈鹏. 特发性肺纤维化患者外周血单个核细胞T淋巴细胞亚群及Th1/Th2型细胞因子的检测[J]. J4, 2008, 34(2): 282-284.
[10]	杨俊玲，尹金植，李青山，马忠森. 实验性肺纤维化小鼠IL-1和TNF-α的动态表达及其意义[J]. J4, 2007, 33(3): 522-525.
[11]	孙文铸, 毕黎琦. 大鼠肺纤维化形成过程中IGF-Ⅰ和TGF-β₁的表达[J]. J4, 2007, 33(2): 231-233.
[12]	刘冰，李璐，刘洋，刘军. 中药合剂对博莱霉素所致人染色体断裂的拮抗作用[J]. J4, 2006, 32(3): 443-444.
[13]	杨俊玲，吴艳峰，董春玲，马忠森. 肺纤维化小鼠肺泡灌洗液及肺组织中IL-10和TGF-β₁的动态表达[J]. J4, 2005, 31(4): 536-538.
[14]	彭丽萍，左梦华，迟宝荣. 甲基强地松龙治疗特发性肺间质纤维化前后TNF-α和IL-8的变化[J]. J4, 2004, 30(2): 286-288.